Skip to main content

Table 4 Secondary outcomes

From: In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Characteristic rFSH hMG-HP p-value All Patients
Mean (SD)oocyte yield (number of oocytes retrieved) (All patients) 10.80 (6.02) 9.77 (5.53) <0.01 10.53 (5.91)
   (≤35 years) 11.21 (6.11) 10.28 (5.6) <0.01 10.98 (6.0)
   (≥36 years) 9.93 (5.74) 8.83 (5.27) <0.01 9.62 (5.63)
Mean (SD) mature oocyte yield (All Patients) 8.58 (5.27) 7.72 (4.59) <0.01 8.35 (5.11)
   (≤35 years) 8.80 (5.35) 8.08 (4.66) <0.01 8.62 (5.19)
   (≥36 years) 8.09 (5.06) 7.08 (4.38) <0.01 7.80 (4.9)
Number of embryos transferred (fresh) 1.91 (0.86) 1.96 (0.68) <0.01 1.93 (0.81)
   (≤35 years) 1.89 (0.84) 1.94 (0.63) <0.01 1.91 (0.79)
   (≥36 years) 1.96 (0.89) 2.00 (0.76) <0.01 1.97 (0.85)
Mean number of oocytes/embryos frozen per cycle All patients 2.14 (3.29) 1.7 (2.8) <0.01 2.02 (3.18)
   (≤35 years) 2.32 (3.4) 1.8 (2.85) <0.01 2.18 (3.27)
   (≥36 years) 1.77 (3.03) 1.51 (2.68) <0.01 1.70 (2.94)
Number of embryos thawed and used in FET** cycles† (All patients) 0.74 (0.97) 0.67 (0.93) <0.01 0.74 (0.97)
   (≤35 years) 0.67 (0.95) 0.57 (0.9) <0.01 0.67 (0.94)
   (≥36 years) 0.91 (1.03) 0.87 (0.99) <0.01 0.91 (1.02)
  1. * Statistical significance for outcomes assessed via Wilcoxon two sample test and two sample T-test
  2. † Statistical significance assessed via the two sample T-test only
  3. ** FET - Frozen Embryo Transfer
\